Today: 1 July 2026
Xero share price slides 3.7% as ASX tech sells off — what to watch next week
20 February 2026
1 min read

Xero share price slides 3.7% as ASX tech sells off — what to watch next week

Sydney, Feb 20, 2026, 18:17 AEDT — The market is now closed.

Xero Limited (ASX: XRO) ended Friday down 3.7% at A$77.54, with Australia’s information technology sector off 2.4%. The S&P/ASX 200 edged lower by 0.05%. WiseTech Global lost 3.8%, and Megaport tumbled 11.8%.

Still, Xero shares slid, despite the company highlighting fresh AI-driven automation tools. Xero plans to launch its AI data capture and extraction for UK users in the first half of March, just ahead of the April 6 start for Britain’s Making Tax Digital for Income Tax, which will require digital bookkeeping and quarterly reports. “Data entry doesn’t have to be done manually any more,” said UK managing director Kate Hayward. Xero

Risk appetite held uneven beyond Australia as the weekend approached. Oil climbed to levels not seen in six and a half months following U.S. President Donald Trump’s 10-15 day ultimatum to Iran on its nuclear program. Traders also leaned into Nvidia’s earnings due next week. “Today seems like a good day to stay out of trouble,” Spectra Markets president Brent Donnelly remarked. Reuters

Timing is key for Xero holders. The stock serves as a barometer for appetite toward software-as-a-service names, with investors gauging how much they’re prepared to pay for companies banking on recurring subscriptions over single licence sales.

Xero shares bounced between A$76.95 and A$80.86 on Friday, still hovering close to the low end of their 52-week band—A$72.26 to A$196.52. At this level, the stock sits roughly 61% under its peak.

The company’s main business is cloud accounting software, plus extras like payroll and payments. Lately, it’s been pushing the idea that AI can handle more routine jobs—think sorting receipts, picking out invoice details—but still keeps the product from feeling like just another commodity.

Monday’s open is set to show if that late-week drop was simple housekeeping or something more troubling. Oil prices, bond yields, and U.S. tech action are likely to steer sentiment, while local earnings numbers can quickly ripple through the market.

Still, there’s a nagging risk here. Should AI succeed in slashing bookkeeping costs and speeding things up across the board, software vendors could find themselves locked in a price war instead of battling over features.

Xero faces its own hurdles with payments and its U.S. push, as it works to expand the platform with Melio. If costs start to outpace the returns, that’s likely to weigh on the stock.

Xero’s FY26 results are due out May 14, and that’s when investors can expect more details about Melio and how the company’s doing stateside.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • ASX Eyes Small Gains; Dow Hits Another High as AI Rally Lifts Tech
    June 30, 2026, 6:27 PM EDT. ASX futures edged up 0.1%, pointing to a flat or slightly firmer open. The Australian dollar picked up a bit to 69.2 US cents but is still down 3.4% for the month. In the US, strong AI buying drove tech stocks higher and helped push the Dow to another record close at 53,219, up 0.3%. Nvidia rose 2.6%, Apple jumped 2.7%, AMD surged 7.7%, and Intel added 6%. The market stayed positive, even as some investors questioned if big AI bets will pay off long term. The S&P 500 gained 0.8% and the Nasdaq rose 1.5%.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop